109
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Soluble urokinase plasminogen activator receptor informs on the progression course after multiple injuries

, , , , , & show all
Pages 660-664 | Received 16 Nov 2015, Accepted 13 Feb 2016, Published online: 27 Apr 2016
 

Abstract

Purpose: The purpose of this study is to study the use of soluble urokinase plasminogen activator receptor (suPAR) for the prognosis of multiple organ dysfunction (MOF) after multiple traumas.

Methods: Serum suPAR was measured within the first 24 h after multiple injuries in 85 patients. Measurements were repeated after 4 d or at sepsis onset.

Results: Odds ratio for trauma-associated MOF was 4.09 (p: 0.026) with admission suPAR greater than 8 ng/ml. More than 40% increases of suPAR were associated with odds ratio 9.33 (p: 0.047) for severe sepsis.

Conclusions: suPAR is a useful surrogate biomarker for development of MOF and severe sepsis after multiple traumas.

Disclosure statement

None of the authors has any conflict of interest related to this submission.

Funding information

The study was funded in part by (a) the Hellenic Institute for the Study of Sepsis; and (b) an unrestricted educational grant by ViroGates SA, Copenhagen, Denmark (Grant 70/3/10570) to the University of Athens. The funders had no role in study design, acquisition and analysis of data and in decision to publish.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.